Stay updated on Long-Term Safety of Galegenimab in Geographic Atrophy Clinical Trial
Sign up to get notified when there's something new on the Long-Term Safety of Galegenimab in Geographic Atrophy Clinical Trial page.

Latest updates to the Long-Term Safety of Galegenimab in Geographic Atrophy Clinical Trial page
- Check3 days agoChange DetectedA new revision tag (v3.6.6) has been displayed, indicating a platform version update. This metadata change does not affect the study content or the information presented to users.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe page displays a new revision number (v3.6.5), indicating a minor behind-the-scenes update to the site's backend or documentation.SummaryDifference0.0%

- Check39 days agoChange DetectedThe page now shows Revision: v3.6.4, replacing Revision: v3.6.3. This appears to be a routine platform update rather than a substantive change to the study details.SummaryDifference0.0%

- Check61 days agoChange DetectedThe page shows a new revision tag (v3.6.3), indicating a recent update to the page's content or template. This update changes only metadata and does not modify the core study information presented.SummaryDifference0.0%

- Check68 days agoChange DetectedThe page's revision label changed from v3.6.0 to v3.6.2. This appears to be an internal version update with no changes to study details or layout.SummaryDifference0.0%

- Check82 days agoChange DetectedEnrollment status now states No longer looking for participants, signaling that recruitment for the study is closed. New guidance and navigation items were added (How to Read a Study Record, Common Questions, How to Join a Study), and a formatting change to the Intervention/Treatment header alongside a version update to Revision: v3.6.0.SummaryDifference0.4%

Stay in the know with updates to Long-Term Safety of Galegenimab in Geographic Atrophy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Long-Term Safety of Galegenimab in Geographic Atrophy Clinical Trial page.